Brought to you by 
Cel-Sci nets $4.1mm privately
24 Sep 2009
Executive Summary
Cel-Sci (cancer and infectious disease therapeutics) has netted $4.1mm through the registered direct offering of 9.7mm common shares at $0.45 each (an 8% discount) to selected institutional investors, including Platinum Partners, Midsummer Investment, Whalehaven Capital Fund, and Alpha Capital. The buyers also received five-year Series C warrants to buy an additional 4.85mm shares at $0.55. Chardan Capital Markets was the placement agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cel-Sci nets $4.1mm privately
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice